GlobalData on MSN22h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Hosted on MSN20h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Hosted on MSN15h
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Coinbase issued guidance for the 2025 fiscal year’s first quarter. It sees subscription and services revenue from $685 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback